Tag:

RNAi

Latest Headlines

Latest Headlines

Alnylam COO on Novartis RNAi pullout: Big Pharma has 'never been able to innovate'

The COO of RNAi specialist Alnylam was critical of Big Pharma in the wake of Novartis' decision to slam the breaks on its RNAi research. The news made investors nervous about the future of the promising, but nascent technology and Alnylam stock price is down more than 20% in the last week.

Novartis slams the brakes on once-ambitious RNAi development efforts

Novartis is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. The pharma giant, which has extensive research operations in the Boston area, confirmed the decision, saying that the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move.

The year in nanotech drug delivery

Here at FierceDrugDelivery, we write often about innovations in nanotechnology as it becomes more and more important in the delivery field. These advances are mostly in the very early stages, but they're still promising as the delivery field moves even further into the nanoscale.

Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient

Arrowhead, fresh off a $120 million public offering in February, is paving the way on what it has called a "functional cure" for hepatitis B, beginning dosing in a Phase IIa trial for its RNAi drug designed to deliver the genetic material to the nucleus using a polymer-based conjugate.

Alnylam, MIT team develops RNA-delivering nanoparticles for the liver

Scientists from Alnylam teamed with MIT researchers to develop a new nanoparticle platform with which to better deliver the genetic material to the liver. With MIT professor Robert Langer as one of its authors, the team published a paper in the journal  Proceedings of the National Academy of Sciences  highlighting its particles, which are inspired by the vehicles the body uses to transport cholesterol.

The most influential people in biopharma today

Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...

Amid RNAi buzz, Arcturus touts positive preclinical results

San Diego-based Arcturus Therapeutics added some juice to the RNAi buzz this week at the J.P. Morgan Healthcare Conference with results from a preclinical study that showed a hefty knockdown of the genetic disease transthyretin-mediated amyloidosis.

Merck writes off RNAi, punts Sirna to Alnylam for $175M

While Roche and Sanofi are expanding their investments in RNAi, Merck is getting out.

Sanofi grabs a $700M stake in Alnylam as it ups the ante on RNAi

Sanofi is doubling down on its RNAi development deal with Alnylam. The pharma giant says it will pay a hefty premium to buy up a 12% stake in the biotech, investing $700 million and greatly expanding its rights to Alnylam's lead drug along with a portfolio of current and prospective therapies.

Austrian team improves RNAi 'hairpin' structures for more efficient delivery

Back in 2006, Andrew Fire and Craig Mello won the Nobel Prize in Physiology or Medicine for their discovery of RNA interference in "silencing" genes. Today, nearly a decade later, the technology is still in limbo due to difficulties delivering the genetic material to cells.